EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Conditional cancer-specific survival in breast cancer with de novo bone metastases: A SEER-based study

Shilong Wang, Long Jia

Biomolecules and Biomedicine · 30.09.2026

DOI: 10.17305/bb.2026.14614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 30.09.2026. Verfasst von Shilong Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Medical and Pharmaceutical University Hospital, Binzhou, China; Shandong Medical and Pharmaceutical University, Binzhou, China. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Baseline survival estimates do not capture evolving prognosis in breast cancer with de novo bone metastases. We aimed to develop and internally evaluate a prognostic framework integrating baseline and conditional cancer-specific survival (CSS) estimates. Using the Surveillance, Epidemiology, and End Results (SEER) database, we retrospectively analysed 4,013 women diagnosed in 2010–2015 and randomly allocated 70% to training and 30% to internal validation. Random survival forest-assisted variable selection and Cox proportional hazards regression were used to construct baseline and conditional survival nomograms. Seven predictors were retained: age, primary tumour surgery, nodal stage, molecular subtype, and concomitant brain, liver, and lung metastases. The validation concordance index was 0.662 (95% confidence interval: 0.642–0.681), indicating moderate discrimination. Model-averaged probabilities of surviving to 10 years conditional on 5-year survival were 43.0% and 43.7% in training and validation, respectively, compared with unconditional CSS estimates of 17.2% and 17.7%. Landmark calibration was satisfactory for predicting subsequent 3-year CSS among 3-year survivors; other conditional scenarios were not empirically validated. The framework may support updated prognostic assessment once initial treatment status is known. However, 10-year estimates remain exploratory because of limited late follow-up and non-proportional hazards, and external validation is needed before clinical application.

Autor:innen und Institutionen

  • Shandong Medical and Pharmaceutical University Hospital, Binzhou, China; Shandong Medical and Pharmaceutical University, Binzhou, China.

Zitieren

APA

Wang, S., & Jia, L. (2026). Conditional cancer-specific survival in breast cancer with de novo bone metastases: A SEER-based study. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2026.14614

Vancouver

Wang S, Jia L. Conditional cancer-specific survival in breast cancer with de novo bone metastases: A SEER-based study. Biomolecules and Biomedicine. 2026. doi:10.17305/bb.2026.14614

BibTeX
@article{Wang2026,
  author = {Wang, Shilong and Jia, Long},
  title = {Conditional cancer-specific survival in breast cancer with de novo bone metastases: A SEER-based study},
  journal = {Biomolecules and Biomedicine},
  year = {2026},
  doi = {10.17305/bb.2026.14614}
}
Kostenlos starten →